Lecicarbon Dospelí

Sodium hydrogen carbonate and sodium dihydrogen phosphate, the active ingredient in Lecicarbon Dospelí, is a buffering agent presented as a rectal formulation for rectal use. It helps adjust local pH in the lower gastrointestinal tract, neutralizing excess acidity during certain diagnostic or therapeutic procedures.

GNH USA supplies Lecicarbon Dospelí as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality for global healthcare providers today.

Lecicarbon Dospelí is employed to modify rectal pH and support related clinical procedures.

- Diagnostic rectal examinations: facilitates optimal visualization by neutralizing acidic conditions. - Enema therapy adjunct: provides buffering capacity to improve patient comfort during enema administration. - Local acidity relief: helps reduce discomfort caused by excess rectal acidity in certain gastrointestinal conditions.

Lecicarbon Dospelí may cause local and systemic adverse reactions, which are categorized by frequency.

Common Side Effects: - Rectal irritation: mild burning or itching at the application site. - Abdominal discomfort: transient cramping or bloating. - Flatulence: increased gas production. - Nausea: mild feeling of queasiness.

Serious or Rare Side Effects: - Electrolyte imbalance: significant changes in sodium or phosphate levels. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Rectal bleeding: unexpected hemorrhage from the mucosa. - Metabolic alkalosis: elevated blood pH due to excessive buffering.

Before using Lecicarbon Dospelí, consider the following precautions. - Pregnancy: use only if clearly needed and prescribed by a healthcare professional. - Breastfeeding: consult a physician before administration. - Renal impairment: monitor electrolyte levels closely. - Existing electrolyte disorders: avoid in patients with hypernatremia or hyperphosphatemia. - Concomitant alkalinizing agents: assess risk of excessive pH shift. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Lecicarbon Dospelí can interact with other medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Systemic alkalinizing drugs: may cause severe metabolic alkalosis. - High‑sodium medications: increase risk of hypernatremia.

Moderate Interactions (Monitor Closely): - Antacids: can alter local pH balance. - Diuretics: may affect electrolyte status. - ACE inhibitors: potential potassium disturbances. - Oral phosphate supplements: risk of additive phosphate load.